Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts
Bloomberg•3/17
🤖 AI Summary
📌 Background:
HSBC has turned bearish on Eli Lilly & Co. shares for the second time in a year.
The firm believes investor expectations for weight-loss drugs are overinflated.
💬 Comment:
Eli Lilly's stock dipped following HSBC's downgrade, highlighting potential overvaluation concerns regarding weight-loss drug market expectations.